Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lawrence Eichenfeld
Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies
Main Article Content Lawrence Eichenfeld University of California, San Diego, School of Medicine Eric Simpson Oregon Medical Research Center, Portland, OR, USA Kim Papp Probity Medical Research, Waterloo, ON, Canada Jacek Szepietowski Wroclaw Medical University, Wroclaw, Poland Leon Kircik Mount Sinai Darryl Toth XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada Seth Forman ForCare Clinical Research, Tampa, FL, USA Michael Kuligowski Incyte Corporation, Wilmington, DE,...
Phase IV Evaluation of the Adrenal Suppression Potential and PKPD of Halobetasol Propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis
Main Article Content Adelaide Herbert UT Health McGovern Medical School, Houston, TX, USA Rhonda Schreiber Mayne Pharma Debbie Glaab Mayne Pharma Lawrence Eichenfeld UC San Diego Keywords halobetasol foam, adrenal suppresion, psoriasis Abstract N/A References 1. Bronker et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs (2015) 17:373–384. DOI 10.1007/s40272-015-0137-1. 2. Paller et al.
Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2 | SKIN The Journal of Cutaneous Medicine
Main Article Content Lawrence Eichenfeld UC San Diego Elaine Siegfried St. Louis University, St. Louis, MO Pearl Kwong Solutions Through Advanced Research, Jacksonville, FL Susan Cutler Verrica Pharmaceuticals Inc, West Chester, PA Cynthia Willson Verrica Pharmaceuticals Inc, West Chester, PA Pamela Rumney Verrica Pharmaceuticals Inc, West Chester, PA Christine Crosby Verrica Pharmaceuticals Inc, West Chester, PA Jennifer Andres Verrica Pharmaceuticals Inc, West Chester, PA Mark McBride...
Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies | SKIN The Journal of Cutaneous Medicine
Main Article Content Andrew Blauvelt Oregon Medical Research Center, Portland, OR, USA Lawrence Eichenfeld UC San Diego Michael Kuligowski Incyte Corporation, Wilmington, DE, USA May Venturanza Incyte Corporation, Wilmington, DE, USA Kang Sun Incyte Corporation, Wilmington, DE, USA Jonathan Silverberg George Washington University School of Medicine Keywords safety, ruxolitinib cream, atopic dermatitis, phase 3 study Abstract N/A References 1. Langan SM, et al. Lancet. 2020;396(10247):345-360. 2.
Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program | SKIN The Journal of Cutaneous Medicine
Main Article Content Lawrence Eichenfeld UC San Diego Jonathan Silverberg George Washington University School of Medicine Robert Bissonnette Innovaderm Research Inc., Montreal, QC, Canada Anna Tallman Dermavant Sciences, Inc., Morrisville, NC, USA David Rubenstein Dermavant Sciences, Inc., Morrisville, NC, USA Stephen Piscitelli Dermavant Sciences, Inc., Morrisville, NC, USA John Jett Dermavant Sciences, Inc., Morrisville, NC, USA Keywords tapinarof, atopic dermatitis, ADORING trial Abstract...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lawrence
Contact Lawrence, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack